These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8004566)

  • 1. Oral etoposide in the treatment of hormone-refractory prostate cancer.
    Hussain MH; Pienta KJ; Redman BG; Cummings GD; Flaherty LE
    Cancer; 1994 Jul; 74(1):100-3. PubMed ID: 8004566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
    Pienta KJ; Redman B; Hussain M; Cummings G; Esper PS; Appel C; Flaherty LE
    J Clin Oncol; 1994 Oct; 12(10):2005-12. PubMed ID: 7523606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
    Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
    Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
    Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ
    J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
    Mackler NJ; Pienta KJ; Dunn RL; Cooney KA; Redman BG; Olson KB; Fardig JE; Smith DC
    Clin Genitourin Cancer; 2007 Jun; 5(5):318-22. PubMed ID: 17645828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.
    Hussain M; Wolf M; Marshall E; Crawford ED; Eisenberger M
    J Clin Oncol; 1994 Sep; 12(9):1868-75. PubMed ID: 8083710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
    Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
    Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
    Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
    Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.
    Naito S; Ueda T; Kotoh S; Kumazawa J; Itoh K; Sagiyama K; Omoto T; Andoh S; Hasegawa Y; Fujisawa Y
    Cancer Chemother Pharmacol; 1995; 35(3):225-9. PubMed ID: 7805181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
    Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
    J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer].
    Matsuda H; Nonomura K; Nagamori S; Shinohara N; Koyanagi T; Maru A; Matsuno T; Fujieda J; Minami S; Morita H
    Nihon Hinyokika Gakkai Zasshi; 1995 Oct; 86(10):1530-7. PubMed ID: 7474602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer.
    Olver IN; Stephenson J; Schulze D
    Cancer Chemother Pharmacol; 2000; 46(4):338-41. PubMed ID: 11052632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients.
    Maulard-Durdux C; Dufour B; Hennequin C; Chrétien Y; Delanian S; Housset M
    Cancer; 1996 Mar; 77(6):1144-8. PubMed ID: 8635136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer].
    Ushiyama T; Ihara H; Kurita Y; Kageyama S; Ueda D; Mugiya S; Yamaguchi Y; Nakano M; Suzuki K; Kawabe K
    Hinyokika Kiyo; 1993 Dec; 39(12):1139-44. PubMed ID: 8285162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.
    Pienta KJ; Redman BG; Bandekar R; Strawderman M; Cease K; Esper PS; Naik H; Smith DC
    Urology; 1997 Sep; 50(3):401-6; discussion 406-7. PubMed ID: 9301705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
    Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on etoposide therapy of relapsing prostatic cancer patients].
    Moriyama M; Murai T; Kondoh I
    Hinyokika Kiyo; 1990 Jul; 36(7):777-81. PubMed ID: 2239575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.